Friday, June 16, 2017 5:29:47 AM
"While the asset still faces a certain level of clinical and regulatory risk, we believe ND0612 is becoming sufficiently de-risked at this point to attract a potential M&A suitor. Our view is supported by recent reports stating that NDRM has retained a financial advisor for the possible sale of the company, according to Bloomberg."
https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Upgrades+Neuroderm+Ltd+%28NDRM%29+to+Outperform%3B+Alleged+Takeover+Discussions+Pump+New+Life+into+ND0612/13009512.html
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM